Pharmacology
News
FDA OKs new drug for Fabry disease
“The totality of clinical data suggests that Elfabrio has the potential to be a long-lasting therapy.”
News
FDA approves first drug to treat Alzheimer’s agitation
“Agitation is one of the most common and challenging aspects of care among patients with dementia due to Alzheimer’s disease.”
News
Two phase 3 trials show benefits of dupilumab for prurigo nodularis
The results “support the involvement of type 2 cytokines in driving PN disease pathogenesis and the targeting of the IL-4/IL-13 axis as a novel...
News
FDA expands use of dapagliflozin to broader range of HF
The sodium-glucose cotransporter 2 inhibitor was previously approved in the United States for adults with heart failure with reduced ejection...
Opinion
Medications that scare me
Many medications can cause cardiac symptoms and other serious side effects in elderly patients.
Conference Coverage
Phase 3 trial: Maribavir yields post-transplant benefits
Study findings “provide supportive evidence of the potential for long-term benefit” with maribavir for the treatment of post-transplant CMV.
Conference Coverage
Teriflunomide delays MS symptoms in radiologically isolated syndrome
The data support the theory that treatment should begin early in patients with a high likelihood of developing symptomatic MS on the basis of...
Conference Coverage
New drugs in primary care: Lessons learned from COVID-19
Nirmatrelvir-ritonavir has helped keep many patients out of the hospital, says internist.
News
“Terrific progress”: Adding blinatumomab for infant leukemia
Immunotherapy plus chemotherapy improves outcomes and may soon become first-line treatment for a rare pediatric blood cancer.
News
FDA puts partial hold on investigational alopecia areata drug deuruxolitinib
The announcement came after a pulmonary embolism occurred with the 12-mg twice-daily dose in one of the long-term open-label extension studies.